Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.570
+0.110 (2.47%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 5.63, with a low estimate of 3.00 and a high estimate of 7.50. The average target predicts an increase of 23.19% from the current stock price of 4.57.
Analyst Consensus: Hold
* Price targets were last updated on Jan 8, 2026.
Analyst Ratings
The average analyst rating for Cytek Biosciences stock from 4 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy Maintains $4 → $5 | Strong Buy | Maintains | $4 → $5 | +9.41% | Jan 8, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $7.5 | Buy | Maintains | $8 → $7.5 | +64.11% | Nov 11, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +53.17% | May 28, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Sell Maintains $3.5 → $3 | Strong Sell | Maintains | $3.5 → $3 | -34.35% | May 12, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +31.29% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
212.42M
from 201.49M
Increased by 5.42%
Revenue Next Year
227.35M
from 212.42M
Increased by 7.03%
EPS This Year
-0.17
from -0.52
EPS Next Year
-0.14
from -0.17
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 219.2M | 236.8M | |
| Avg | 212.4M | 227.4M | |
| Low | 203.6M | 210.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.8% | 11.5% | |
| Avg | 5.4% | 7.0% | |
| Low | 1.1% | -0.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.01 | 0.03 | |
| Avg | -0.17 | -0.14 | |
| Low | -0.25 | -0.23 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.